ReCAP

Therapeutic Considerations in Adults With Hidradenitis Suppurativa


 

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent boils, abscesses, and nodules that can progress to narrow channels that form under the skin. An estimated 1%-4% of the US population has the condition, and women are affected more commonly than men.

Treatment of HS is challenging and the pathogenesis is still under investigation. Many believe that the disease involves follicular occlusion that leads to perifollicular cyst development followed by ruptures of the cyst contents. Many drug classes, including antibiotics and topical therapies, as well as lifestyle modifications, have been used to successfully treat mild to moderate HS. Management of moderate to severe HS has been less successful, however.


Dr Jennifer Hsiao, from the University of Southern California, highlights the various approaches to HS treatment, including medical, procedural, and emerging options.

--

Jennifer Hsiao, MD, Associate Professor, Physician, Department of Dermatology, University of Southern California, Los Angeles, California

Jennifer Hsiao, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Novartis; UCB

Serve(d) as a speaker or a member of a speakers bureau for: AbbVie

Recommended Reading

Is There an Association Between Hidradenitis Suppurativa and Fibromyalgia?
MDedge Dermatology
Adalimumab enhances primary wound closure after HS surgery
MDedge Dermatology
Squamous Cell Carcinoma in Hidradenitis Suppurativa Lesions Following Tumor Necrosis Factor α Inhibitors
MDedge Dermatology
Two studies add to knowledge base of biosimilar use in psoriasis, HS
MDedge Dermatology